Drug Name:
ONCASPAR Rx
Generic Name and Formulations:
Pegaspargase 750 IU/mL; soln for IV or IM inj; preservative-free.
Company:
Shire US, Inc.
Therapeutic Use:
Indications for ONCASPAR:
First-line acute lymphoblastic leukemia (including patients with asparaginase hypersensitivity).
Adults and Children:
Give by IV inj over 1–2hrs or by IM inj (max 2mL/inj site). 2500 IU/m2 no more frequently than every 14 days.
Contraindications:
History of pancreatitis, serious hemorrhage, or thrombosis with prior L-asparaginase therapy.
Warnings/Precautions:
Have resuscitation equipment available and observe patient for 1hr post-dose. Monitor serum glucose, coagulation parameters. Discontinue if serious allergic reactions, thrombotic events, or pancreatitis occur. Monitor for hepatotoxicity and abnormal liver function. Pregnancy (Cat.C). Nursing mothers: not recommended.
Pharmacological Class:
Enzyme.
Adverse Reactions:
Allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, CNS thrombosis, coagulopathy, hyperbilirubinemia, elevated transaminases, hyperlipidemia.
How Supplied:
Single-use vial (5mL)—1
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- The Symbiosis of Headache and Sleep
- Neurosurgery in Parkinson Disease: A Brief History and Look Forward
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Blood Pressure-Dementia Link May Be Affected by Population Characteristics
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Micronutrient Levels May Be Altered in ADHD
- MIND Diet Linked to Slower Cognitive Decline Among Stroke Survivors
- Ozanimod Superior to Interferon β-1a for Treatment of Relapsing Multiple Sclerosis
- Comorbidity More Likely With Chronic Migraine vs Episodic Migraine
- Eptinezumab for Frequent Episodic Migraine: Results of Phase 3 PROMISE-1 Study